Key result
Depleting B cells with an anti-CD20 antibody prevented MI-induced accelerated atherosclerosis and IgG accumulation in plaques in an ApoE-/- mouse model.
Why the study?
MI accelerates atherosclerosis, and because post-MI B cell-derived autoantibodies persist for years, the role of B cells in adaptive immune responses to MI required investigation.
Does B cell depletion or modulation prevent MI-accelerated atherosclerosis in an ApoE-/- mouse model?
Does B cell depletion or modulation prevent MI-accelerated atherosclerosis in an ApoE-/- mouse model?
Early B-cell activation and autoantibody production post-MI drive accelerated atherosclerosis, suggesting B-cell targeted therapies could prevent recurrent cardiovascular events.
B-cell depletion merits human trials for post-MI secondary prevention; leaves open clinical translation from this mouse model.
AIMS: Myocardial infarction (MI) accelerates atherosclerosis and greatly increases the risk of recurrent cardiovascular events for many years, in particular, strokes and MIs. Because B cell-derived autoantibodies produced in response to MI also persist for years, we investigated the role of B cells in adaptive immune responses to MI. METHODS AND RESULTS: We used an apolipoprotein-E-deficient (ApoE-/-) mouse model of MI-accelerated atherosclerosis to assess the importance of B cells. One week after inducing MI in atherosclerotic mice, we depleted B cells using an anti-CD20 antibody. This treatment prevented subsequent immunoglobulin G accumulation in plaques and MI-induced accelerated atherosclerosis. In gain of function experiments, we purified spleen B cells from mice 1 week after inducing MI and transferred these cells into atherosclerotic ApoE-/- mice, which greatly increased immunoglobulin G (IgG) accumulation in plaque and accelerated atherosclerosis. These B cells expressed many cytokines that promote humoural immunity and in addition, they formed germinal centres within the spleen where they differentiated into antibody-producing plasma cells. Specifically deleting Blimp-1 in B cells, the transcriptional regulator that drives their terminal differentiation into antibody-producing plasma cells prevented MI-accelerated atherosclerosis. Alarmins released from infarcted hearts were responsible for activating B cells via toll-like receptors and deleting MyD88, the canonical adaptor protein for inflammatory signalling downstream of toll-like receptors, prevented B-cell activation and MI-accelerated atherosclerosis. CONCLUSION: Our data implicate early B-cell activation and autoantibodies as a central cause for accelerated atherosclerosis post-MI and identifies novel therapeutic strategies towards preventing recurrent cardiovascular events such as MI and stroke.
No takes yet. Share an insight, caveat, or question.
Kyaw et al. (2020) studied Myocardial infarction-accelerated atherosclerosis. B cell depletion (anti-CD20 antibody) vs. Control (implied) was evaluated on MI-induced accelerated atherosclerosis and IgG accumulation in plaques. Depleting B cells with an anti-CD20 antibody prevented MI-induced accelerated atherosclerosis and IgG accumulation in plaques in an ApoE-/- mouse model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: